South Carolina is currently home to 1221 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Charleston, Greenville, Spartanburg and Columbia. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis
Recruiting
A randomized, double-blind, placebo-controlled multicenter, phase 3 study to evaluate the efficacy and safety of tezepelumab administered subcutaneously (SC) using an accessorized pre-filled syringe (APFS) versus placebo in adult and adolescent patients with eosinophilic esophagitis (EoE).
Gender:
All
Ages:
Between 12 years and 80 years
Trial Updated:
03/26/2024
Locations: Research Site, Greenville, South Carolina
Conditions: Eosinophilic Esophagitis
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
Recruiting
The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP) and talquetamab SC in combination with daratumumab SC (Tal-D), respectively, with daratumumab SC in combination with pomalidomide and dexamethasone (DPd).
Gender:
All
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Relapsed or Refractory Multiple Myeloma
A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies
Recruiting
The purpose of this study is to evaluate the efficacy and safety of Nipocalimab versus placebo in participants with active idiopathic inflammatory myopathies (IIM).
Gender:
All
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: ACME Research Arthritis and Osteoporosis Center, Orangeburg, South Carolina
Conditions: Myositis
Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer
Recruiting
The purpose of the study in Part 1 (dose escalation) and in Part 2 (dose expansion) is to determine the recommended Phase 2 dose(s) (RP2D[s]) and evaluate preliminary clinical efficacy. Part 3 (dose expansion) will confirm safety and preliminary clinical activity at the RP2D.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: Carolina Urologic Research Center, Myrtle Beach, South Carolina
Conditions: Urinary Bladder Neoplasms, Receptors, Fibroblast Growth Factor
Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma
Recruiting
This is a randomised, placebo-controlled, double-blind study to assess the efficacy and safety of Atuliflapon administered once daily over a 12-week treatment period to adult participants with moderate to severe uncontrolled asthma.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
03/26/2024
Locations: Research Site, Columbia, South Carolina
Conditions: Asthma
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
Recruiting
The purpose of this study is to evaluate the efficacy of JNJ-78934804 at Week 48 compared to guselkumab and golimumab.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
03/26/2024
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Crohn's Disease
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
Recruiting
The purpose of this study is to evaluate the efficacy and safety of JNJ-78934804 as compared to guselkumab and golimumab in participants with moderately to severely active ulcerative colitis who have had an inadequate initial response, loss of response, or intolerance to one or more approved advanced therapy.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
03/26/2024
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Colitis, Ulcerative
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies
Recruiting
This study will evaluate the efficacy, safety, and pharmacokinetics of mosunetuzumab subcutaneous (SC) formulation in participants with selected B-cell malignancies (types of non-Hodgkin's lymphoma [NHL]).
Gender:
All
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: Prisma Health Cancer Institute; Research Pharmacy, Greenville, South Carolina
Conditions: Non-Hodgkin Lymphoma
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
Recruiting
The purpose of this study is to evaluate the efficacy and safety of nipocalimab compared to placebo in participants with generalized myasthenia gravis (gMG).
Gender:
All
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Myasthenia Gravis
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder
Recruiting
The purpose of this study is to evaluate the anti-tumor effects of TAR-200 in combination with intravenous (IV) cetrelimab and IV cetrelimab alone.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: Carolina Urologic Research Center, Myrtle Beach, South Carolina
Conditions: Urinary Bladder Neoplasms
A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years
Recruiting
The purpose of this study is to demonstrate the efficacy of 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) compared to placebo in the prevention of the first invasive extraintestinal pathogenic Escherichia coli disease (IED) event caused by ExPEC9V O-serotypes.
Gender:
All
Ages:
60 years and above
Trial Updated:
03/26/2024
Locations: Hugh D. Durrence, MD, PC, Charleston, South Carolina
Conditions: Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)
Recruiting
Semaglutide is a medicine studied in patients with NASH. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabetes in many countries. Participants will either get semaglutide or a dummy medicine - which treatment participants get is decided by chance. Participants will need to inject themselves with medicine under the skin. Participants will need to do this once a week. The study will last for about 5 years. Participants will have up to 21 clinic visits a... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: Medical University Of South Carolina, Charleston, South Carolina
Conditions: Non-alcoholic Steatohepatitis